Text Size
32 studies found for:    "familial mediterranean fever"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed
Has Results 		Rilonacept for Treatment of Familial Mediterranean Fever (FMF)
Condition: Familial Mediterranean Fever
Interventions: Drug: Rilonacept;   Drug: Placebo
2 Completed Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever
Condition: Familial Mediterranean Fever
Intervention: Drug: Canakinumab
3 Withdrawn Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission
Condition: Familial Mediterranean Fever
Intervention:
4 Not yet recruiting Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever
Condition: Familial Mediterranean Fever,
Intervention: Drug: Kineret
5 Active, not recruiting Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)
Condition: Colchicine Resistant/Intolerant Familial Mediterranean Fever
Intervention: Drug: Canakinumab
6 Recruiting Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
Condition: Periodic Disease
Intervention:
7 Completed Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients
Condition: Familial Mediterranean Fever
Intervention: Drug: colchicine sprinkle capsules
8 Unknown † Magnetic Resonance (MR) Spectroscopy In Familial Mediterranean Fever (FMF) Patients
Condition: Familial Mediterranean Fever
Intervention:
9 Enrolling by invitation Heat Intolerance in the Group of FMF Patients
Conditions: Familial Mediterranean Fever;   Heat Intolerance;   Heat Tolerance Test
Intervention:
10 Completed Internleukin-1 Trap to Treat Autoinflammatory Disease
Conditions: Inflammation;   Familial Mediterranean Fever;   Still's Disease, Adult-Onset
Intervention: Drug: IL-1 Trap
11 Recruiting Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency
Conditions: Mevalonic Aciduria;   Mevalonate Kinase Deficiency;   Immune System Diseases;   Periodic Fever Syndromes, Hereditary;   Lipid Metabolism, Inborn Errors
Intervention:
12 Active, not recruiting Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic (Tumor Necrosis Factor)TNF-receptor Associated Periodic Syndrome (TRAPS)
Condition: TNF-receptor Associated Periodic Syndromes (TRAPS)
Intervention: Biological: ACZ885
13 Recruiting Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Condition: DIRA
Intervention: Drug: Rilonacept
14 Terminated Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease
Conditions: NOMID;   CINCA Syndrome
Intervention: Drug: Canakinumab
15 Completed
Has Results 		Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Conditions: Familial Cold Autoinflammatory Syndrome (FCAS);   Familial Cold Urticaria;   Muckle-Wells Syndrome (MWS);   Genetic Diseases, Inborn
Interventions: Drug: rilonacept 160 mg;   Drug: Placebo
16 Completed The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
Condition: Cryopyrin Associated Periodic Syndrome
Intervention: Drug: canakinumab (company code: ACZ885D)
17 Recruiting Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
Conditions: Nervous System Malformations;   Arthropathy, Neurogenic;   Urticaria;   Papilledema
Intervention: Drug: Anakinra
18 Recruiting B7 Coreceptor Molecules in Hyper IgD Syndrome Form of Mevalonate Kinase Deficiency
Conditions: Hyper IgD Syndrome;   Mevalonate Kinase Deficiency
Intervention:
19 Recruiting Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
Conditions: Cryopyrin-associated Periodic Syndromes (CAPS);   Familial Cold Autoinflam Syn (FCAS);   Muckle-wells Syn (MWS);   Neonatal Onset Multisystem Inflam Disease (NOMID)
Intervention:
20 Completed Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Biological: canakinumab
To Top

Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results
† Indicates status has not been verified in more than two years